Editas Medicine, Inc. (EDIT) |
|
7.25 0.22 (3.13%)
|
03-31 16:00 |
|
Open: |
7.1 |
Pre. Close: |
7.03 |
|
High:
|
7.37 |
Low:
|
7.05 |
|
Volume:
|
1,588,425 |
Market Cap:
|
500(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:18:15 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 9.82 One year: 10.85 |
| Support: |
Support1: 7 Support2: 5.82 |
| Resistance: |
Resistance1: 8.41 Resistance2: 9.28 |
| Pivot: |
7.78  |
| Moving Average: |
MA(5): 7.25 MA(20): 7.94
MA(100): 9.4 MA(250): 12.1 |
| MACD: |
MACD(12,26): -0.6 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 12.5 %D(3): 11.6 |
| RSI: |
RSI(14): 36.7 |
| 52-week: |
High: 20.04 Low: 7 |
| Average Vol(K): |
3-Month: 1,722 (K) 10-Days: 1,501 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EDIT ] has closed above bottom band by 25.0%. Bollinger Bands are 12.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.53 - 7.57 |
7.57 - 7.6 |
|
Low:
|
6.9 - 6.94 |
6.94 - 6.98 |
|
Close:
|
6.95 - 7.02 |
7.02 - 7.09 |
|
Company Description |
|
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. |
Headline News |
Fri, 24 Mar 2023
Why Is Editas (EDIT) Down 21% Since Last Earnings Report? - Nasdaq
Tue, 14 Mar 2023
An investment is made in Editas Medical, Inc. by Twinbeech Capital ... - Best Stocks
Mon, 13 Mar 2023
Twinbeech Capital LP Takes Position in Editas Medicine, Inc ... - MarketBeat
Mon, 13 Mar 2023
A few Editas Medicine, Inc. (NASDAQ:EDIT) insiders sold shares in the last 12 months: Not a good sign for shareholders - Simply Wall St
Sat, 11 Mar 2023
Editas Medicine, Inc. receives a $271,000 investment from Verition ... - Best Stocks
Thu, 09 Mar 2023
26796 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Bought by ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
69 (M) |
|
% Held by Insiders
|
6.719e+007 (%) |
|
% Held by Institutions
|
0.4 (%) |
|
Shares Short
|
20,940 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.1961e+008 |
|
EPS Est Next Qtl
|
-0.77 |
|
EPS Est This Year
|
-2.89 |
|
EPS Est Next Year
|
-2.85 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
146.2 |
|
Return on Equity (ttm)
|
-23.8 |
|
Qtrly Rev. Growth
|
1.971e+007 |
|
Gross Profit (p.s.)
|
-25.06 |
|
Sales Per Share
|
-25.38 |
|
EBITDA (p.s.)
|
-8.17105e+007 |
|
Qtrly Earnings Growth
|
-3.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-177 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-1.7 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.29 |
|
Price to Cash Flow
|
2.56 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.916e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
